Progerie

Overview

Hutchinson-Gilford progeria syndrome (HGPS, usually called Progeria) is an ultra-rare genetic condition in which most affected children carry a new, non-inherited change in the LMNA gene that causes cells to make progerin, a harmful version of the structural protein lamin A. It causes severe growth failure, loss of body fat and hair, joint and bone problems, and rapidly progressive artery disease, while intelligence is generally preserved. Without targeted treatment, death from cardiovascular or cerebrovascular disease occurs at an average age of about 14.5 years; with lonafarnib, average survival is approximately 18.7 years. GeneReviews: Hutchinson-Gilford Progeria Syndrome (ncbi.nlm.nih.gov)

The current standard of care combines multidisciplinary monitoring and supportive management with lonafarnib (Zokinvy), an oral farnesyltransferase inhibitor that reduces mortality risk but does not correct the underlying mutation or eliminate progerin. In the U.S. prescribing evidence base, lonafarnib-treated patients had an average survival increase of 2.5 years at the latest follow-up versus matched untreated patients; common adverse effects include gastrointestinal symptoms, infection, reduced appetite, fatigue, and weight loss. Zokinvy prescribing information (dailymed.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been unusually focused for a rare disease because roughly 90% of people with classic HGPS have the same LMNA c.1824C>T variant, creating a shared molecular target. The dominant questions are whether progerin can be prevented, selectively removed, or permanently corrected in the tissues most responsible for fatal disease—especially blood vessels and the heart—and whether these approaches can be delivered safely to children. The field has advanced from drug repurposing toward gene editing and RNA-targeted therapies, but no curative treatment has yet demonstrated safety or benefit in people. GeneReviews: Hutchinson-Gilford Progeria Syndrome In vivo base editing rescues HGPS in mice (ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The most important curative-direction result remains adenine base editing, a form of gene editing that changes one DNA letter without making a double-strand DNA break. In 2021, researchers used an adenine base editor to correct the causative LMNA variant in patient-derived fibroblasts and in HGPS-model mice. In cells, editing corrected 87%–91% of disease alleles; in mice, a single AAV9-vector treatment restored normal RNA splicing, reduced progerin, improved vascular pathology, and increased median lifespan from 215 to 510 days. This is strong proof of principle for correcting the root cause, but it remains preclinical. In vivo base editing rescues HGPS in mice (pubmed.ncbi.nlm.nih.gov)

A second major strategy is RNA therapy, which aims to stop production of progerin without permanently changing DNA. Two 2021 Nature Medicine studies identified antisense compounds that block the abnormal splicing event that produces progerin. One optimized peptide-conjugated morpholino, SRP-2001, reduced progerin RNA in the aorta of HGPS-model mice, preserved vascular smooth-muscle cells, and increased lifespan by 61.6%; a separate systematic screen of 198 antisense oligonucleotides found lead compounds that lowered progerin RNA and extended lifespan in mice. Targeted antisense therapy for HGPS Systematic antisense-oligonucleotide screening (pubmed.ncbi.nlm.nih.gov)

RNA-targeting research has also broadened to CRISPR-Cas13, an RNA-cutting system designed to distinguish progerin messenger RNA from normal LMNA transcripts. A 2025 study delivered RfxCas13d with a progerin-targeting guide into patient cells and HGPS-model mice, reporting reduced progerin, improved nuclear and cardiac features, better vascular pathology, and longer mouse survival. Unlike permanent DNA editing, this approach is potentially reversible, but it has only been tested preclinically and still requires a clinically suitable delivery system. RfxCas13d progerin targeting (pmc.ncbi.nlm.nih.gov)

Small-molecule approaches remain important because they can be given orally and combined with lonafarnib. Progerinin (SLC-D011) is designed to disrupt the harmful interaction between progerin and lamin A. In patient-derived cells and mouse models, it improved premature-senescence features, increased body weight, and extended lifespan, supporting its transition into a human study; however, these animal results should not be interpreted as proof of a cure in people. Progerinin preclinical study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The principal active recent trial is a Phase 2a, randomized, open-label study of progerinin plus lonafarnib versus lonafarnib alone at Boston Children’s Hospital, sponsored by PRG Science & Technology and supported in collaboration with The Progeria Research Foundation. The study started on January 13, 2025, enrolled 10 participants, and was listed as active but not recruiting in its February 9, 2026 registry update. Its main objectives are dose selection, safety, tolerability, pharmacokinetics, and changes in plasma progerin; no results had been posted in that registry record. NCT06775041: Progerinin in HGPS (clinicaltrials.gov)

A Phase I/II trial of everolimus plus lonafarnib, intended to test whether stimulating cellular autophagy could improve on lonafarnib alone, had been completed by the March 2025 GeneReviews update, with results still pending. Meanwhile, plasma-progerin testing has become a practical trial tool: a 2023 study developed a sensitive blood assay and found that lonafarnib reduced plasma progerin by an average of 35 %–62 %, with the depth and duration of reduction associated with survival. GeneReviews: Hutchinson-Gilford Progeria Syndrome Plasma progerin immunoassay (ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

Researchers use patient-derived fibroblasts, induced pluripotent stem-cell models, and several genetically engineered mouse models carrying human or mouse equivalents of the HGPS-causing variant. These systems allow investigators to measure correction of LMNA splicing, progerin protein reduction, nuclear shape, vascular smooth-muscle-cell survival, arterial fibrosis, heart function, body weight, and lifespan. The central delivery platforms are AAV vectors for in vivo gene editing and viral or oligonucleotide-based delivery for RNA-directed approaches. In vivo base editing rescues HGPS in mice RfxCas13d progerin targeting (pubmed.ncbi.nlm.nih.gov)

Blood progerin is emerging as a key biomarker because it can provide an earlier indication of biological response than survival studies alone in an ultra-rare disease. The validated plasma assay is particularly useful for evaluating therapies meant to reduce production or accumulation of progerin and is incorporated into the current progerinin trial. Plasma progerin immunoassay NCT06775041: Progerinin in HGPS (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The field is driven by a tightly connected network that includes the National Institutes of Health, the Broad Institute of MIT and Harvard, Harvard-associated hospitals including Boston Children’s Hospital and Dana-Farber Cancer Institute, Brown University and Hasbro Children’s Hospital, and academic groups in South Korea working on progerinin and RNA-targeting platforms. The Progeria Research Foundation (PRF) provides patient registries, diagnostic testing, a cell and tissue bank, clinical-trial coordination, grants, and research convening; as of December 2024, PRF reported funding 85 grants to 69 principal investigators at 55 institutions in 14 countries. PRF research programs and impact (progeriaresearch.org)

Funding and translational capacity have recently shifted toward making gene editing manufacturable for human use. PRF reported net assets of approximately $47.4 million in its 2024 annual-report materials, largely linked to proceeds from sale of a Priority Review Voucher, and in March 2026 announced a manufacturing agreement with Forge Biologics for SamPro-2, PRF’s investigational AAV base-editing therapy. The partnership is intended to produce clinical-grade material and move the program toward regulatory review and human trials. [PRF 2024 annual-report materials] [PRF–Forge SamPro-2 manufacturing partnership]

Strengths, Limitations, and Challenges

The greatest strength of the Progeria field is biological precision: most classic HGPS is driven by one recurrent DNA change, and the relevant toxic product—progerin—can be measured in cells, tissues, and now blood. Lonafarnib has established that lowering the impact of progerin can improve survival, while gene editing, antisense compounds, and RNA-targeting systems have shown that reducing or correcting progerin can substantially improve vascular disease and lifespan in mice. Zokinvy prescribing information In vivo base editing rescues HGPS in mice Plasma progerin immunoassay (dailymed.nlm.nih.gov)

The central limitations are translation, safety, and scale. Results in short-lived mouse models may not predict lifelong benefit in children; gene editors must reach enough vascular and cardiac cells, avoid harmful unintended edits, and be evaluated for durable safety. RNA therapies may avoid permanent DNA changes but must achieve selective, sustained delivery, while small molecules such as progerinin must first show a favorable safety and efficacy profile in the very small available patient population. SamPro-2’s 2026 manufacturing agreement is an important enabling milestone, but it also underscores that base-editing therapy had not yet entered human efficacy testing. RfxCas13d progerin targeting PRF–Forge SamPro-2 manufacturing partnership (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

A cure is scientifically plausible but not yet close enough to claim a timeline. The milestones to watch are published Phase 2a progerinin data; confirmation that plasma-progerin reductions predict meaningful cardiovascular benefit; initiation of first-in-human testing for SamPro-2 or another gene-editing program; and evidence that editing or RNA suppression safely reaches the cardiovascular tissues that determine survival. The most realistic near-term outcome is improved combination treatment, whereas a one-time genetic cure will require successful human delivery, safety, and durable clinical benefit beyond the compelling mouse results. NCT06775041: Progerinin in HGPS PRF–Forge SamPro-2 manufacturing partnership In vivo base editing rescues HGPS in mice (clinicaltrials.gov)

Références

• GeneReviews: Hutchinson-Gilford Progeria Syndrome — Gordon, Brown et Collins; University of Washington, 2025.
• Zokinvy prescribing information — DailyMed, 2024.
• In vivo base editing rescues HGPS in mice — Koblan et al., Nature, 2021.
• Targeted antisense therapy for HGPS — Erdos et al., Nature Medicine, 2021.
• Systematic antisense-oligonucleotide screening — Puttaraju et al., Nature Medicine, 2021.
• RfxCas13d progerin targeting — Chae et al., Molecular Therapy, 2025.
• Progerinin preclinical study — Kang et al., Communications Biology, 2021.
• NCT06775041: Progerinin in HGPS — ClinicalTrials.gov, updated 2026.
• Plasma progerin immunoassay — Gordon et al., Circulation, 2023.
• PRF research programs and impact — The Progeria Research Foundation, 2024.
• PRF 2024 annual-report materials — The Progeria Research Foundation, 2025.
• PRF–Forge SamPro-2 manufacturing partnership — The Progeria Research Foundation, 2026.